These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22920905)

  • 1. Heat shock protein 90 inhibitors as broad spectrum anti-infectives.
    Rochani AK; Singh M; Tatu U
    Curr Pharm Des; 2013; 19(3):377-86. PubMed ID: 22920905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors.
    Murillo-Solano C; Dong C; Sanchez CG; Pizarro JC
    Malar J; 2017 Jul; 16(1):292. PubMed ID: 28724415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
    Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
    Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus.
    Lamoth F; Juvvadi PR; Steinbach WJ
    Crit Rev Microbiol; 2016; 42(2):310-21. PubMed ID: 25243616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.
    Boroumand N; Saghi H; Avan A; Bahreyni A; Ryzhikov M; Khazaei M; Hassanian SM
    J Pharm Pharmacol; 2018 Feb; 70(2):151-158. PubMed ID: 28980313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock proteins and cancer: How can nanomedicine be harnessed?
    Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
    J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
    Whitesell L; Lin NU
    Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hsp90 chaperone machinery: from structure to drug development.
    Hahn JS
    BMB Rep; 2009 Oct; 42(10):623-30. PubMed ID: 19874705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens.
    Cowen LE
    Curr Opin Microbiol; 2013 Aug; 16(4):377-84. PubMed ID: 23588026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 from neglected protozoan parasites.
    Roy N; Nageshan RK; Ranade S; Tatu U
    Biochim Biophys Acta; 2012 Mar; 1823(3):707-11. PubMed ID: 22198098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
    Soga S; Akinaga S; Shiotsu Y
    Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90: a promising broad-spectrum antiviral drug target.
    Wang Y; Jin F; Wang R; Li F; Wu Y; Kitazato K; Wang Y
    Arch Virol; 2017 Nov; 162(11):3269-3282. PubMed ID: 28780632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 as a therapeutic target in patients with oesophageal carcinoma.
    Ekman S; Bergqvist M; Tell R; Bergström S; Lennartsson J
    Expert Opin Ther Targets; 2010 Mar; 14(3):317-28. PubMed ID: 20148718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.